Analyst activity on Sunday pointed to a notable split in sentiment. Medtech names drew the most scrutiny. ISRG saw its consensus target price trimmed to $558 from $562. The $144B robotic surgery giant remains well-loved on the Street — 22 buys versus just two sells — but the marginal pullback suggests some price-target fatigue at current levels.
PODD also took a small target cut, to $237 from $239. Insulet's diabetes-device franchise carries a similarly bullish consensus with 22 buys, but bears are circling. Short interest sits at 7.4% of free float.
BSX saw its target dip to $73.34. All 25 covering analysts remain at hold or buy, but the slight reduction reflects post-earnings caution in the broader medtech space.
On the industrial side, HON received a target bump to $248, with six buys on the board. UNP picked up a small lift to $297.
The standout fresh call was GWW, which received a new recommendation at a $1,273 average target. The industrial distributor carries a $65B market cap and light short interest of just under 3%.
KEYS also received a new recommendation at $387, an upgrade on the prior consensus, reflecting improving test-and-measurement demand.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
